Repurposing JAK inhibitors to treat type 1 diabetes [ 2018 - 2021 ]

Research Grant

Researchers: A/Pr Helen Thomas (Principal investigator) ,  Dr Stuart Mannering ,  Prof Thomas Kay

Brief description Type 1 diabetes occurs when the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Beta cells have to respond to molecules called cytokines for T cells to be able to kill them. We have identified a drug, called a JAK inhibitor, which will block the effects of cytokines on beta cells and cells of the immune system. The goal of this work is perform pre-clinical assessment of this drug, and test whether it has effects on type 1 diabetes in people.

Funding Amount $AUD 961,143.82

Funding Scheme Project Grants

Notes Standard Project Grant